3D MEDICINES (01244) released its annual performance, with a net loss of 178 million yuan attributable to shareholders, narrowing by 2.81% year-on-year.

23:36 31/03/2026

Sino Biopharmaceutical Limited (01244) announced its annual performance for the year ending December 31, 2025. The group achieved a revenue of 356 million yuan during the period, a decrease of 20.1% year-on-year. The net loss attributable to the owners of the parent company was 178 million yuan, narrowing by 2.81% year-on-year. The basic loss per share was 0.72 yuan.

3D MEDICINES (01244) released its annual performance for the year ending on December 31, 2025. The group achieved a revenue of 356 million yuan during the period, a decrease of 20.1% year-on-year. The loss attributable to the owners of the parent company was 178 million yuan, a decrease of 2.81% year-on-year. The basic loss per share was 0.72 yuan.

LINK HOLDINGS (08237) released its annual financial performance, with a net profit attributable to shareholders of HK$178 million, turning a loss into profit compared with the previous year.

JISHENG GP HLDG (08133) announces financial results for 2025 with a net loss attributable to owners of the company of HK$3.977 million, representing a year-on-year increase of approximately 1.05 times.

ZIJING INTL FIN (08340) announces annual performance with a shareholder loss of 7.437 million Hong Kong dollars, a year-on-year increase of 200.24%.

LINK HOLDINGS (08237) released its annual financial performance, with a net profit attributable to shareholders of HK$178 million, turning a loss into profit compared with the previous year.

ZIJING INTL FIN (08340) announces annual performance with a shareholder loss of 7.437 million Hong Kong dollars, a year-on-year increase of 200.24%.